Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report released on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Stock Down 22.1 %

Shares of APVO stock opened at $0.28 on Tuesday. The firm’s 50-day moving average is $0.27 and its 200-day moving average is $0.55. Aptevo Therapeutics has a 52-week low of $0.14 and a 52-week high of $15.14.

Aptevo Therapeutics (NASDAQ:APVO) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.26. Sell-side analysts forecast that Aptevo Therapeutics will post -2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.